FDA clears Amgen’s Prolia for glucocorticoid osteoporosis
US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture.
23rd May 2018
Latest news
Clinigen, Mitsubishi link for early access programme
Clinigen says it has partnered with Mitsubishi Tanabe Pharma to initiate a Managed Access Program in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (ALS).
23rd May 2018
UK streams £30m into global fight against AMR
The UK government has announced that it will stream £30 million into global efforts to fight antimicrobial resistance (AMR).
23rd May 2018
EU approves Repatha for reduction of CV risk
The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha to include the reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease (CVD).
23rd May 2018
Pfizer begins testing RSV vaccine in healthy adults
Pfizer has kicked off an early stage trial of an experimental vaccine against respiratory syncytial virus (RSV) in healthy adult volunteers.
23rd May 2018
US clears paediatric use of GSK’s Arnuity Ellipta
GlaxoSmithKline’s inhaled corticosteroid Arnuity Ellipta has been approved in the US for paediatric use.
22nd May 2018
Community services are being neglected, warns NHS Providers
NHS Providers is calling for a greater focus on community services after finding that they have not been given enough priority at both local and national level to reach their potential.
22nd May 2018
Novo’s Refixia beats rival in head to head trial
Novo Nordisk’s Refixia has come out on top in a head to head study assessing its effect in patients with the bleeding disorder haemophilia B against Swedish Orphan Biovitrum’s recombinant factor IX-Fc fusion protein (rFIXFc).
22nd May 2018
EU nod for ViiV/Janssen's two-drug HIV regimen
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.
22nd May 2018
Trial findings back wider use of Roche’s Hemlibra
Data from two late-stage studies further support use of Roche’s Hemlibra in a much broader population of haemophilia patients.
22nd May 2018
US green light for AZ’ Lokelma
US regulators have finally issued a green light for AstraZeneca’s Lokelma as a treatment for hyperkalaemia - elevated potassium levels in the blood - in adult patients.
21st May 2018
Data show ‘enduring’ benefits of GSK’s Nucala
GlaxoSmithKline has released long-term data showing that its biologic Nucala significantly decreased exacerbations in patients with severe, eosinophilic asthma as well as improvement in disease control.
21st May 2018
EMA confirms risks of MS drug Zinbryta
The European Medicines Agency has concluded that the risks linked with use of Biogen and AbbVie's multiple sclerosis drug Zinbryta outweigh its benefits.
21st May 2018
AI should be used to detect chronic disease, says PM
Prime Minister Theresa May has revealed new plans to prevent thousands of cancer deaths and improve the detection of chronic diseases through greater use of artificial intelligence.
21st May 2018
US OK’s first-in-class drug Aimovig for migraine prevention
Amgen and Novartis’ Aimovig has become the first anti-CGRP therapy to win regulatory clearance in the US, winning approval for migraine prevention.
18th May 2018
